Impact of Inflation Reduction Act on Insulin Costs for Medicare Beneficiaries

A recent study published in JAMA by the USC Schaeffer Center for Health Policy & Economics reveals the positive impact of the Inflation Reduction Act (IRA) on insulin costs for Medicare beneficiaries. By instituting a $35 monthly cap on insulin expenses, the act aims to alleviate financial burdens and reduce the necessity for seniors to ration essential medication due to cost concerns.

The research highlights a significant reduction in out-of-pocket expenses for insulin users following the cap's implementation in January 2023. Notably, the average monthly cost decreased by 21%, saving beneficiaries approximately $5 monthly. This reduction has led to more consistent out-of-pocket expenses, contrasting previous instances of fluctuating costs. Beneficiaries with previously high monthly expenditures saw the most relief, with costs halved and resulting in an 8% increase in prescription fills, along with a 5% rise in days with available insulin supplies.

For many Medicare beneficiaries, overall insulin utilization remained stable due to existing support structures. Programs like Medicare’s Low-Income Subsidy and the Senior Savings Model had already mitigated costs for most users. Prior to the IRA's implementation, only a small proportion of insulin prescriptions exceeded the new cost cap, emphasizing the policy's targeted approach.

Lead author Rebecca Myerson highlighted the importance of targeting future caps toward patients with high out-of-pocket costs, especially those without insurance. The study acknowledges state government and insulin manufacturer efforts to enhance affordability and notes anticipated savings from recent FTC settlements.

Legislative efforts are underway to extend the monthly cap benefits to private insurance plans and support uninsured individuals. This could yield substantial savings, such as the projected $170 million reduction in out-of-pocket expenses for insulin users anticipated in 2024.

Co-author Dana Goldman stressed the clinical significance of improving medication adherence by reducing patient expenses. Minimizing out-of-pocket costs is essential for enhancing health outcomes. The study's authors include John Romley, Dima Mazen Qato, Erin Trish, Anne Peters, and Ying Cao, supported by funding from the National Institute of Diabetes and Digestive and Kidney Diseases.